Osteosarcoma is the second leading cause of cancer-related death for children and young adults. In this study, we have subcutaneously injected-with and without matrigel-athymic mice (Fox1nu/nu) with human osteosarcoma 3AB-OS pluripotent cancer stem cells (CSCs), which we previously isolated from human osteosarcoma MG63 cells. Engrafted 3AB-OS cells were highly tumorigenic and matrigel greatly accelerated both tumor engraftment and growth rate. 3AB-OS CSC xenografts lacked crucial regulators of beta-catenin levels (E-cadherin, APC, and GSK-3beta), and crucial factors to restrain proliferation, resulting therefore in a strong proliferation potential. During the first weeks of engraftment 3AB-OS-derived tumors expressed high levels of pAKT, beta1-integrin and pFAK, nuclear beta-catenin, c-Myc, cyclin D2, along with high levels of hyperphosphorylated-inactive pRb and anti-apoptotic proteins such as Bcl-2 and XIAP, and matrigel increased the expression of proliferative markers. Thereafter 3AB-OS tumor xenografts obtained with matrigel co-injection showed decreased proliferative potential and AKT levels, and undetectable hyperphosphorylated pRb, whereas beta1-integrin and pFAK levels still increased. Engrafted tumor cells also showed multilineage commitment with matrigel particularly favoring the mesenchymal lineage. Concomitantly, many blood vessels and muscle fibers appeared in the tumor mass. Our findings suggest that matrigel might regulate 3AB-OS cell behavior providing adequate cues for transducing proliferation and differentiation signals triggered by pAKT, beta1-integrin, and pFAK and addressed by pRb protein. Our results provide for the first time a mouse model that recapitulates in vivo crucial features of human osteosarcoma CSCs that could be used to test and predict the efficacy in vivo of novel therapeutic treatments.
O steosarcoma, the most common of primary bone malignancies, is among a group of mesenchymal cancers characterized by clinical, histologic and molecular heterogeneity, and karyotypes with a high degree of aneuploidy [Smida et al., 2010] . It is a highly aggressive tumor with a high metastasizing potential and, at present, it remains the second leading cause of cancer-related death for children and young adults [Ta et al., 2009] . The current standard protocol of a three-drug chemotherapy regimen, using cisplatin, doxorubicin, and high-dose methotrexate, results in no more than 70% long-term disease-free survival for osteosarcoma patients without metastasis [Wesolowski and Budd, 2010] . There is no established second-line chemotherapy for relapsed osteosarcoma, and therefore new therapeutic approaches are urgently needed.
It is well established that most solid tumors are hierarchically organized and that their growth is sustained by a distinct subpopulation of cells, termed cancer stem cells (CSCs) [Clevers, 2011] , which represent the source for tissue renewal and hold malignant potential [Li and Neaves, 2006; Maitland and Collins, 2008] . CSCs confer resistance to therapies; thus, a successful cure of cancer should require CSCs eradication.
We have recently demonstrated that prolonged treatments (about 100 days) of human osteosarcoma MG63 cells with 3-aminobenzamide (3-AB), a potent competitive inhibitor of poly(ADP-ribose)-polymerase (PARP), induce massive cell death followed by progressive enrichment of a new CSC population named 3AB-OS. This 3AB-OS CSC line [Di Fiore et al., 2009 ] has been recently patented (''Pluripotent cancer stem cells: Their preparation and use' '. FI2008A000238. 11/12/2008 . N. PCT/IB2009/055690, 11/12/2009) and represents a pluripotent, heterogeneous, and stable cell population, which has been characterized at the molecular [Di Fiore et al., 2009] and genetic level [Di Fiore et al., paper submitted] . Overall, our results have suggested that the original human osteosarcoma MG63 cells might contain a rare population of multipotent CSCs, which has been selected and enriched by 3AB treatment.
The translation of therapeutic strategies for osteosarcoma from the experimental phase into the clinic has been limited by insufficient animal models bearing the basic features of human tumors. Generating an appropriate and reliable experimental model of human cancer is crucial to identify and test possible antitumor strategies.
Xenograft models obtained through transplantation of cancer cell lines into immunodeficient mice are very useful to analyze the molecular mechanisms underlying tumor development and to identify novel molecular therapeutic approaches. Tumor cell xenografts can be readily accepted by immunocompromised mice, such as athymic nude mice bearing a genetic mutation that causes thymic aplasia and results in an inhibited immune system [Sharkey and Fogh, 1984] . The athymic nude mouse can receive many different types of tissue and tumor grafts providing a model that is easy to manage, easy to establish, and very effective for testing tumor treatments; it is characterized by a consistent and reproducible cell growth and permits easy access to the tumor for treatment, caliper measurement, and imaging evaluation, representing, therefore, a useful model for studying the biology and response to therapies of human tumors in vivo. Here, we report a xenograft model of human osteosarcoma CSCs that could be clinically relevant. Because of the distinctive capability of CSCs to recapitulate the development of the original tumors in vivo, human osteosarcoma 3AB-OS CSC xenografts into nude mice might provide an avenue for testing in vivo approaches to pathway-targeted drug discovery and preclinical screening and to investigate the behavior of human osteosarcoma CSCs.
MATERIALS AND METHODS

CELL LINES AND CULTURE CONDITIONS
The human osteosarcoma MG63 cells were acquired from Interlab Cell Line Collection (Genova, Italy). The human 3AB-OS CSCs were generated in our laboratory [Di Fiore et al., 2009] . 3AB-OS and MG63 cells were cultured as monolayers in Dulbecco's modified Eagle medium (DMEM), supplemented with 10% (v/v) heat inactivated fetal bovine serum, 2 mM L-glutamine, and penicillinstreptomycin antibiotics (50 mg/ml) (Euroclone, Pero, Italy) in a humidified atmosphere of 5% CO 2 in air at 378C. When cells grew to approximately 80% confluence, they were subcultured or harvested using 0.25% trypsin-EDTA (Life Technologies Ltd).
MATRIGEL
BD Matrigel
TM , purchased from BD Biosciences-Discovery Labware, Becton Dickinson, (Buccinasco, Italy), is a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma. It polymerizes under normal physiological conditions to produce a reconstituted, biologically active matrix, which favors cell attachment and differentiation. As BD Matrigel rapidly gels at 22-358C, it was thawed overnight at 48C, aliquoted on ice into pre-cooled sterile microcentrifuge tubes and then frozen at À208C until use. All procedures involving Matrigel were carried out at 48C on ice to prevent polymerization.
CELL LINES AND MOUSE XENOGRAFT GENERATION
MG63 and 3AB-OS cells were proven to be free of mycoplasma infection by reverse-transcriptase polymerase chain reaction (RTPCR) (Takara Shuzo Co, Ltd, Kyoto, Japan) of supernatant from densely growing cells. MG63 and 3AB-OS cells to be implanted were harvested at approximately 80% confluence, washed in phosphate-buffered saline (PBS) (Life Technologies Ltd), resuspended in serum-free culture medium, counted in a hemocytometer, and equilibrated at a density of 3 Â 10 6 cells per 150 ml DMEM. Cell viability was assessed through trypan blue staining. MG63 cells and 3AB-OS cells (3 Â 10 6 ) were both prepared in either DMEM or DMEM/Matrigel (1/1 mixture), into a final volume of 300 ml for injection. Cells were injected subcutaneously into the flank of 4-week old male athymic nude mice. Male athymic nude mice (Foxn1nu/nu), carrying a disruption of the forkhead box n1 gene [Coffer and Burgering, 2004] , which leads to thymic atrophy and immunodeficiency [Nehls et al., 1996] , were purchased from Harlan, Udine, Italy. Mice were acclimated for 1 week before the start of this study. 
MOUSE HEALTH AND CONDITION ASSESSMENT AND TUMOR MEASUREMENT
Mice were inspected for tumor appearance, by daily observation and palpation. To minimize pain, discomfort, and distress, all mice were observed daily for their behavior and body weight (BW)-recorded every week-was used as an index of mice-welfare. BCS, which ranges from 1 (emaciation) to 5 (obesity), was determined by visual and hands-on examination of each animal. The hands-on examination was done by holding the mouse by the base of the tail and passing a finger over the sacroiliac bones and vertebral column [Ullman-Culleré and Foltz, 1999] . We established that BCS had not to exceed 2, with BCS ¼ 2 corresponding to ''underconditioned'' (with segmentation of vertebrae and dorsal pelvic bones readily palpable), and the mean tumor size had not to exceed 10% of the mouse BW. Tumor volume was calculated through an external caliper, measuring twice weekly the greatest longitudinal diameter (length) and the greatest transverse diameter (width) and volumes were calculated by the formula ''Tumor volume (mm 3 ) ¼ width 2 Â length Â 0.52 [Euhus et al., 1986; Tomayko and Reynolds, 1989 ]. Mice were sacrificed by cervical dislocation and tumor samples and tissues were collected at 3, 5, and 7 weeks after cell injection. Criteria to indicate marker expression in this study were as follows: The number of positive cells was semiquantitatively evaluated by counting the number of stained cells in 8-10 randomly chosen fields, counting at least 1,000 cells, at high magnification (40Â objective and 10Â eyepiece); four degrees of positivity for PCNA and Ki-67 were identified: ''þþþ'' (75-100%) ; four degrees for other markers were identified: '' À '' no positive cell, '' þ '' 30%, ''þþ'' 31-70%, and ''þþþ'' !71%.
Images of stained tissues were captured using Leica DMR microscope equipped with a Leica DFC 320 digital camera. The images were visualized with epifluorescent filters and transferred to Adobe Photoshop CS4 (Adobe Systems, San Jose, CA).
MITOSIS COUNT
Mitoses were counted in five fields (Â40 lens) on replicate sections stained with toluidine blue which enhances the detection of mitotic figures.
RNA EXTRACTION AND REAL-TIME QUANTITATIVE RT-PCR RNA was extracted from four 20 mm formalin-fixed paraffinembedded (FFPE) sections for each sample. Paraffin was removed by xylene extraction followed by ethanol wash. RNA was isolated from sectioned tissue blocks using the RecoverAll TM Total Nucleic Acid Isolation Kit (Ambion, Life Technologies Corporation); a DNase I treatment step was included. One microgram of total RNA was reverse transcribed in a final volume of 20 ml Reverse transcription (RT) by using a Super-Script First-Strand Synthesis kit for RT-PCR (Invitrogen), according to the manufacturer's instructions. The resulting cDNAs were used for Quantitative real-time PCR (qPCR) using the primers (Proligo, Milan, Italy) reported in Supplementary 2 ml of template cDNA, 12.5 ml of SYBR Green PCR Master Mix 2Â, a final concentration of 300 nM of forward and reverse primers and RNase-free dH2O to a final volume of 25 ml. qPCRs were performed in triplicate and repeated for confirmation. PCR cycling was performed as follows: 958C for 10 min; 958C for 30 s, 608C for 60 s, and 728C for 30 s for 40 cycles; and a final extension at 728C for 5 min. To determine primer specificity, three stages (958C for 15 s, 608C for 20 s, and 958C for 15 s, with a ramping time of 20 min) were added at the end of the PCR to obtain dissociation curves for each gene. To verify that the RT-PCR signals derived from RNA rather than genomic DNA, for each gene tested a control identical to the test assay but omitting the RT reaction (no RT control) was included. qPCR data were analyzed by SDS 2.1 software. Relative transcript levels were determined using the 2-DDCt method and normalized to endogenous b-actin control.
STATISTICAL ANALYSIS
Data were expressed as mean AE SE. Results of in vivo tumorigenicity assays and real-time RT-PCR analyses were evaluated by Student's t-test. Differences were considered significant when P < 0.05.
RESULTS
EVALUATION OF IN VIVO TUMORIGENICITY OF MG63 CELLS AND 3AB-OS CSCS
We have previously shown [Di Fiore et al., 2009 ] that 3AB-OS osteosarcoma cells possess in vitro the most significant properties of CSCs, including the ability to initiate tumors. Here, we have examined in vivo, in xenografted nude mice, the tumor-initiating capacity of both human osteosarcoma 3AB-OS CSCs and parental human osteosarcoma MG63 cells. To examine the tumorigenic potential of both cell lines (MG63 and 3AB-OS) 3 Â 10 6 cells were mixed with either matrigel or cell culture medium and injected subcutaneously into 4 week-old immunocompromised mice. As reported in Table I , mice were subdivided into six groups, each composed of 15 mice. Each group was then further divided into three subgroups corresponding to the times when mice were sacrificed, i.e., at the end of the 3rd, 5th, and 7th week following inoculation (mice were 7, 9, and 11 week-old, respectively), if allowed by health conditions and ethical reasons. Control animals were either uninoculated or inoculated with matrigel. Figure 1A is a representative picture of animals of each group subcutaneously inoculated with cancer cells. As shown in both Table I and Figure 1A , none of the mice inoculated with matrigel alone (0/15) or with MG63 cells alone (0/15) developed tumors. Even if some mice (4/15) co-inoculated with MG63 cells and matrigel developed a modest subcutaneous reaction ( Fig. 1A) , by histology it appeared to be composed of soft fatty tissue only (not shown). Instead, when mice were inoculated with 3AB-OS cells alone, tumors developed in 75% of mice (11/15 mice), or in 100% of mice (15/15 mice) when cells were injected in the presence of matrigel. However, tumor volume strongly depended on both the presence of matrigel and the engraftment time. More precisely, mice coinoculated with 3AB-OS cells and matrigel, developed tumors, which were, at 3 and 5 weeks of engraftment, about 13 and 2.6-times greater than those found in mice inoculated with 3AB-OS cells alone. (Table I and Fig. 1A and B) . As shown in Figure 1B , the trend of tumor growth over time in mice co-inoculated with 3AB-OS cells, with or without matrigel, was similar, although matrigel seemed to greatly accelerate both tumor engraftment and growth rate. Consistently, mice inoculated with 3AB-OS cells alone reached the endpoint (tumor weight had overcome 10% of the BW and mice were sacrificed for ethical reasons) at the 7th week after engraftment, whereas mice engrafted with the same cells in presence of matrigel were sacrificed at the 5th week.
Overall, Table I and Figure 1 show that, while MG63 cells do not possess tumor-forming ability in vivo, 3AB-OS cells are highly tumorigenic and matrigel greatly accelerated both tumor engraftment and growth rate. These results permitted to establish that the 3rd and 5th week of tumor engraftment in the presence of matrigel may be compared to the 5th and 7th week of tumor engraftment in the absence of matrigel. This statement was followed to describe the results reported in the successive paragraphs.
None of the engrafted mice ever developed clinical symptoms suggesting pathogenic human tumor cell dissemination in host tissues. To analyze whether tumor cells engraftment produced metastasis, internal organs of mice (heart, lungs, kidneys, spleen, liver, and brain) were removed, for macroscopic and microscopic analyses, following sacrifice. In our experiments, all inoculated mice remained healthy during the whole period of treatment and metastases were not observed in any of the studied animals. Figure 2 is a representative picture of mouse host tissues, analyzed both macroscopically ( Fig. 2A) and microscopically after staining of FFPE sections with H&E (Fig. 2B) , which shows the absence of any gross histological evidence of damage or cancer cell infiltration.
HISTOLOGY AND PROLIFERATIVE POTENTIAL OF TUMORS DERIVED FROM SUBCUTANEOUSLY INOCULATED 3AB-OS CSCS
First, to confirm that tumors derived from 3AB-OS cells engraftment were composed of human cells, tumor sections were stained with anti-human nuclear antigen monoclonal antibody. In addition, as a control for the specificity of the antibody against human antigens we used a section of mouse liver tissue. As shown in Figure 3A , the tumor section showed a strong reaction with the anti-human nuclear antigen antibody whereas no cross-reactivity was observed in the mouse liver section.
The analysis of 3AB-OS cell-derived tumor grafts has shown some common features that were evidenced in all experimental conditions (with or without matrigel; engraftment at 3, 5, or 7 weeks). Figure 3B -E, which includes representative pictures of the tumor microscopy, shows the gross microscopic appearance of the tumors that were circumscribed by a macroscopic fibrous capsule and pericapsular fibrosis, which was not involved in cell proliferation (Fig. 3B) , and that became thinner during tumor growth (not shown). The tumors appeared well vascularized with several blood vessels passing through; cells contained large vesicular and empty-looking nuclei and a thick, distinct nuclear membrane, with coarse chromatin dispersion; the cytoplasm was . E: Histological analyses of tumors derived from mice injected with 3AB-OS cells either with or without matrigel at 3, 5, and 7 weeks of engraftment (H&E, Original magnification Â200). F: Tumor sections immunostained for PCNA (proliferating cell nuclear antigen) and Ki-67, two of the most frequently used cell proliferation markers. Comparison between the fifth week of 3AB-OS engraftment with matrigel and the 7th week 3AB-OS engraftment in its absence. G: Real-Time PCR analysis of MKI67. mRNA levels were normalized by b-actin. Data were expressed as mean AE SE. P-values were calculated using Student's t-test. Differences were considered significant at Ã P < 0.01.
usually abundant and finely granular, basophilic, with no distinct cell border (Fig. 3C) . Cells, which often appeared multinucleated, showed marked anaplasia-including abnormal forms-numerous mitotic figures (>6 to 40Â), aberrant mitosis (Fig. 3D) . However, tumors also showed some significant histologic differences which depended on the time of tumor development and the presence/ absence of matrigel. Indeed (Fig. 3E) , in the absence of matrigel, at 5 weeks after engraftment, tumors consisted of densely packed cells, sometimes with spindle-like shape, more frequently polygonal, mostly undifferentiated, without morphological organization, and with some blood vessels being visible. After 7 weeks, neoplastic cells showed crowding and overlapping, generated different patterns of organization, including bundles and vortexes, and a greater number of blood vessels crossed the tumor. When the tumors developed in the presence of matrigel, at 3 weeks after engraftment the cells appeared more densely packed than in the absence of matrigel, and polygonal and fusiform cells were much more numerous and organized into bundles that showed strong aspects of differentiation for the presence of muscle fibers. Cells in a rosette-like arrangement were also visible. After 5 weeks (which was the final endpoint for cells injected with matrigel, as reported in Fig. 1 ) aspects of differentiation were more numerous, a much greater number of blood vessels and multinucleated cells were present, and a larger number of muscle fibers crossed the tumor. Therefore, as matrigel seemed to provide a more favorable environment for tumor engrafment, cell growth and differentiation, we also assessed the proliferative state of the cells. To this purpose, tumor sections were immunostained for proliferating cell nuclear antigen (PCNA) and Ki-67, two of the most frequently used cell proliferation markers, which recognize nuclear antigens associated with all the phases of the cell-cycle except G0, with their maximal expression level during the S phase, nearby before the beginning of DNA synthesis [Muskhelishvili et al., 2003] . Comparing the 3rd week of tumor cell engraftment with matrigel with the 5th week of tumor cell engraftment in its absence, we observed a very high index of cell proliferation (with both PCNA and Ki-67 labelling indexes) with a few differences between the two conditions (Table II) . Thereafter, cell proliferation index decreased and its level was much lower in tumor cells engrafted in the presence of matrigel (5th week) than in its absence (7th week, Fig. 3F and Table II) .
Similar results were obtained also by comparing, through Real Time RT-PCR, mRNA extracted from FFPE tumors derived from engraftment in the presence and absence of matrigel. Indeed, the presence of matrigel decreased (À1.4-fold) the mRNA levels of MKI67, encoding the antigen identified by the Ki-67 monoclonal antibody (Fig. 3G) .
Overall, these data suggest that matrigel, interacting with endogenous microenvironment might provide adequate cues to reduce cell proliferation.
CELL LINEAGE AND DIFFERENTIATION STATE OF TUMORS DERIVED FROM 3AB-OS CSCS ENGRAFTMENT
Cultured 3AB-OS cells possess pluripotent stem cell potential, as they are capable of giving rise-under specific inductive conditions-to cell derivatives of the three germ layers (ecto, endo, and mesoderm) [Vento et al., manuscript in preparation] . To evaluate whether 3AB-OS cells preserve in vivo these features of the cultured 3AB-OS cells, we assessed cell lineage and differentiation potential of engrafted 3AB-OS tumor cells (with and without matrigel), by immunohistochemical staining for GFAP (an ectodermal marker), vimentin (a mesodermal marker), and alfa-fetoprotein (an endodermal marker). As shown in both Figure 4 and Table III , at the 3rd week of 3AB-OS cell engraftment in the presence of matrigel, the percentage of tumor cell positivity for the three markers was markedly higher (71, 97, and 61% for GFAP, vimentin, and AFP, respectively) than in tumor cells at the 5th week of engraftment without matrigel (40, 13, and 30% for GFAP, vimentin, and AFP, respectively).
At the 5th week of engraftment in the presence of matrigel, the strong positive levels of the three markers were maintained, whereas in the corresponding samples (at the 7th week of engraftment without matrigel) positivity for the three markers markedly increased (64, 50, and 33%, respectively) thus that, at these engraftment times, a minor difference between the marker levels measured in the presence or absence of matrigel was observed.
Overall, these results suggest that engrafted 3AB-OS CSCs retain their differentiation potential. However, matrigel seems to induce a strong commitment to differentiation along the mesenchymal lineage, consistent with an increased morphological differentiation into muscle fibers, which is probably triggered by matrigel cooperation with the subcutaneous microenvironment.
EVALUATION OF MARKERS REQUIRED FOR STEM CELLS STATE
Our previous results [Di Fiore et al., 2009; Di Fiore et al., paper submitted] have shown that 3AB-OS cells express at high levels most crucial stemness markers (CD133, Oct3/4, hTERT, nucleostemin, Nanog, ABCG2, Lin28B, SOX2, Nestin, and HMGA2) known to be involved in the maintenance of the stem cell status. Here, we measured pluripotency and immortality markers by evaluating immunoreactivity of tumor cells, engrafted with and without matrigel, versus the above reported genes. The results showed that, at the 3rd week of engraftment with matrigel no significant differences were found compared with the 5th week of engraftment without matrigel (not shown), whereas at the 5th week of engraftment with matrigel, tumors were much less immunoreactive than at the 7th week of engraftment without matrigel ( Fig. 5A and Table IV ). More precisely, as reported in the table, comparing the 5th week with matrigel to the 7th week without matrigel, the results show that in the presence of matrigel CD133 immunoreactivity decreased by 37.9%; Lin28B, ABCG2, SOX2, Nanog, and HMGA2, showed a decrease that ranged from 26 to 22%; Nucleostemin (NS), h-TERT, Nestin, and Oct3/4 showed a decrease that ranged from 20 to 17%. Comparing mRNA extracted from FFPE tumors, engrafted with and without matrigel, Real Time RT-PCR assays have shown (Fig. 5B ) that in the presence of matrigel, mRNA levels of OCT4, Nanog, and CD133 were significantly lower than in its absence. Overall, these data suggest that matrigel might have provided the environmental cues for a gradual loss of stemness.
POTENTIAL SIGNALING PATHWAYS INVOLVED IN 3AB-OS CSCS TUMORIGENICITY
Unscheduled cell division is a characteristic of cancer cells. We have previously shown [Di Fiore et al., 2009 ] that 3AB-OS cells express higher levels of cell cycle checkpoint proteins (hyperphosphorylated/inactive pRb E2F1, cyclin D1, E, A, and B1, and cdc2) than parental MG63 cells. 3AB-OS cells also showed a much higher level of nuclear beta-catenin-known to control cyclin D1 expressionand express a greater number of proteins with anti-apoptotic activity (FlipL, Bcl-2, XIAP, IAP1, IAP2, and survivin). Figure 6A and Table V-which describe immunohistochemical analyses of tumor cells at the 3rd week of engraftment in the presence of matrigel, show that tumor cells were strongly positive for the hyperphosphorylated/inactive pRb form (73%), cyclin D2 (85%), and c-Myc (74%). Similar results were obtained at the 5th week of engraftment without matrigel (Table V) . These results indicated a potent activation of cell-cycle transitions, i.e., G1/S and G2/M, and suggested that signaling pathways involved in cell Â400) . B: Oct4, Nanog, and CD133 mRNA levels were determined by real-time PCR analysis and normalized by b-actin. Data were expressed as mean AE SE. P-values were calculated using Student's t-test. Differences were considered significant at survival, proliferation, and invasiveness might be preferentially activated in engrafted 3AB-OS cells. Analyses of Wnt and AKT signaling performed at the same weeks of engraftment described above showed that the cells were negative for GSK-3b, APC, and E-cadherin, suggesting that the canonical WNT signal is disrupted. Instead, cells were highly positive for b1-integrin (61%), pAKT (97%), pFAK (77%), and b-catenin (70%), with these three latter markedly accumulating in the nucleus. Moreover, cells were strongly positive for BCL-2 (96%) and XIAP (98%), thus evidencing the presence of potent antiapoptotic signals (Fig. 6A) . Only a few differences were found comparing tumors engrafted at the 3rd and 5th week with and without matrigel (not shown). Conversely, by comparing the 5th week of engraftment with matrigel to the 7th week of engraftment without matrigel ( Fig. 6B and Table V) , immunohistochemical analyses showed that tumor cells were much less immunoreactive versus cyclin D2, c-Myc, and b-catenin in the presence of matrigel than in its absence. Concomitantly, XIAP and Bcl-2 levels markedly decreased. In addition, in the presence of matrigel pAKT levels potently lowered, while b1-integrin and pFAK levels significantly increased with pFAK and pAKT significantly accumulating in the nucleus. Most intriguingly, in cells engrafted with matrigel hyperphosphorylated pRb levels became undetectable whereas the total pRb levels remained unchanged. Comparing mRNA extracted from FFPE tumors produced by engraftment with and without matrigel, Real Time RT-PCR assay (Fig. 6C) showed that beta-catenin, c-Myc, Bcl-2, and Cyclin D2 expression potently decreased in the presence of matrigel.
Overall, these results suggest that pAkt, b1-integrin, and pFAK signaling pathways are crucial for 3AB-OS cells tumorigenicity. However, when tumor cells reach a high density, matrigel might provide the cues for both restraining cell proliferation and inducing myoblast differentiation.
DISCUSSION
To obtain preclinical results with high predictive value for clinical trials, it is crucial to have reliable in vivo tumor models on which new compounds and novel drug combinations can be evaluated [Céspedes et al., 2006; Troiani et al., 2008] .
The CSC model represents nowadays an expanding field in cancer research that aims to identify the molecular mechanisms by which CSCs arise and acquire their stem-like characteristics and to establish how these cells can be selectively targeted and killed [Giordano et al., 2007] .
Many established models of anti-tumor chemotherapy are based upon the successful propagation of established cell lines of human origin, as subcutaneous xenografts in athymic nude mice. However, although xenografts can provide valuable models for human cancers, many tumors can be difficult to establish [Sharkey and Fogh, 1984; Troiani et al., 2008] thus, the identification of factors that facilitate the growth of xenografts is of great interest. One possible way of improving such assay systems is the use of basement membrane components, as the extracellular matrices underlying epithelial cells (basement membranes) might influence cellular behavior through a variety of regulatory factors.
Matrigel is a solubilized tissue basement membrane matrix, extracted from the EHS mouse tumor, which resembles the complex extracellular environment found in many tissues. A number of articles have shown that matrigel can help to establish xenografts from a variety of cell lines [Topley et al., 1993] .
In this study, aimed at obtaining a suitable in vivo model of human osteosarcoma CSCs, we have subcutaneously injected in athymic mice both 3AB-OS osteosarcoma CSCs (which we previously isolated from MG63 cells [Di Fiore et al., 2009] , and the parental MG63 human osteosarcoma cells, either in the absence or in the presence of matrigel. We have shown that while MG63 cells do not possess tumor-forming ability in vivo, 3AB-OS cells instead were highly tumorigenic and matrigel greatly accelerated both tumor engraftment and growth rate.
Pluripotency and immortality in CSCs depend on the expression of a group of genes (stemness genes) which form a self-organized core of transcription factors required for maintaining stem cell-like features [Chen and Daley, 2008; Meng et al., 2012] . In particular, four factors (Oct4, Sox2, Nanog, and Lin28) are sufficient to reprogram human somatic cells to pluripotent stem cells showing the essential characteristics of embryonic stem (ES) cells [Yu et al., 2007] . These induced pluripotent human stem cells express telomerase activity, cell surface markers and genes that characterize human ES cells, and maintain the developmental potential to differentiate into advanced derivatives of all three primary germ layers [Cox and Rizzino, 2010] .
We have previously shown that 3AB-OS cells have a strong stemness potential as they highly express a large panel of stemnessrelated genes, such as CD133, Nanog, Oct3/4, SOX2, h-TERT, HMGA2, Nucleostemin, ABCG2, Nestin, and Lin28B [Di Fiore et al., 2009; Di Fiore et al., paper submitted] . Here, we have shown that when 3AB-OS cells were engrafted in nude mice, they fully preserved their stemness features. Indeed, during the first weeks of engraftment, both in the presence and absence of matrigel, the stemness-related set of genes (including CD133, Nanog, SOX2, Oct3/ 4, h-TERT, HMGA2, Nucleostemin, ABCG2, Nestin, and Lin28B,) was showed that, during the first weeks of engraftment, both tumor growth and cell proliferation increased, thereafter, over time, these indices significantly lowered, with the presence of matrigel greatly accelerating these events. These findings suggested that matrigel, interacting with the microenvironment, might regulate tumor cell behavior providing the adequate cues for a gradual loss of stemness. Genetic alterations and cytopathological heterogeneity characterize osteosarcomas and contribute to the intractability of the disease [Smida et al., 2010] . Osteosarcoma has been proposed to be a differentiation-flawed disease [Siclari and Qin, 2010] . In numerous tumors during cancer progression a partial or complete loss of E-cadherin has been described [Jeanes et al., 2008; Mohamet et al., 2011] . E-cadherin controls the levels of free-cytosolic b-catenin and loss of E-cadherin results in the disruption of cell-cell adhesion, in increased cytosolic and nuclear b-catenin levels and in increased cell proliferation. Loss of E-cadherin-mediated cell adhesion is one of the key mechanisms involved in metastasis and in epithelialmesenchymal transition [Kalluri and Weinberg, 2009] . However, b-catenin level is also regulated by the b-catenin destruction complex (APC, Axin, GSK3b, and casein kinase), which modulates Wnt pathway through the GSK-3b-APC complex [MacDonald et al., 2009] . Alteration of this system leads to b-catenin stabilization and nuclear accumulation and the consequent transcription of genes (i.e., c-Myc and D cyclins) implicated in self-renewal [Ponce et al., 2011] .
At present, we do not know how CSCs originate in osteosarcomas. However, the hypothesis that cancer arises from a tumorigenic subpopulation of CSCs that, during the course of tumorigenesis, accumulate multiple genetic alterations leading to an altered gene expression pattern [Gisselsson, 2011] , generates the need to analyze CSCs for better understanding disease pathogenesis and for developing specific targeted therapy. We have previously shown [Di Fiore et al., 2009 ] that 3AB-OS cell cycle has an abbreviated G1-S phase accompanied by a strong G2-M transition. In particular, in 3AB-OS cells the pRb protein (which is known to influence the timing of G1-S) is constitutively inactivated through hyperphosphorylation and this is accompanied by high levels of nuclear b-catenin and a potent increase in cyclin D1 (responsible for mediating pRb phosphorylation) with an acceleration of the G1-S phase transition. In addition, 3AB-OS cells express high levels of cyclin B1 and cyclin-dependent kinases cdc-2, which promote G2-M phase transition. Moreover, 3AB-OS cells express many antiapoptotic proteins (FlipL, Bcl-2, XIAP, IAP1, IAP2, and survivin). Overall, our findings suggest that 3AB-OS cells are endowed with a high proliferative capacity.
In this article, we have shown that engrafted tumor cells do not express E-cadherin, APC, and GSK-3beta, thus lacking the crucial regulators of soluble b-catenin levels. However, during the first weeks of engraftment they contain high levels of the phosphorylated form of AKT, pAKT, which has been reported to be necessary for the AKT-dependent up-regulation of b-catenin transcriptional activity [Tian et al., 2004; Fang et al., 2007; Ponce et al., 2011] . Consistently, engrafted tumor cells show high levels of nuclear b-catenin, c-Myc, and cyclin D2, along with the hyperphosphorylated-inactive pRb form, which confirms the lack of brakes to restrain cell proliferation. Similarly, the high levels of the antiapoptotic proteins, Bcl-2 and XIAP, show that the strong proliferative potential of the 3AB-OS cells was not counteracted by apoptosis.
Over time, significant changes were observed in the tumor cell composition of xenografts derived by 3AB-OS co-injection with matrigel. Tumors showed the appearance of blood vessels and muscle fibers that in large number crossed the cancer mass.
Understanding the molecular mechanisms controlling cell fate decisions in mammals is a major objective in CSC research. We have recently shown (paper in preparation) that 3AB-OS cells, under appropriate culture conditions, can be induced to differentiate into derivatives of all three primary germ layers. Here, measuring GFAP (ectodermal), vimentin (mesodermal), and AFP (endodermal) expression, we have shown that engrafted tumor cells fully preserved 3AB-OS multilineage commitment. In addition, a higher expression level of these markers was found in the presence of matrigel mixed cells or prolonging time of engrafment. However, the more interesting aspect concerns mesodermal commitment, as in the presence of matrigel engrafted 3AB-OS cells seemed to meet the appropriate environmental cues for committing along the mesenchymal lineage, with activation of myoblast differentiation. Differentiation of muscle progenitors is a multistep process that involves cell cycle withdrawal, expression of muscle-specific genes, and formation of multinucleated myofibers by cell fusion [Sun et al., 2004] . Moreover, it requires specific, but poorly understood, cell signals. Integrin b1 and FAK have been shown to be required for myoblast differentiation, especially for myotube formation and it has been shown that the integrin/FAK signaling pathway regulates the expression of the promyogenic factors, including MyoD [Han et al., 2011] . It is also known that myoblast differentiation requires dephosphorylation of the retinoblastoma pRb protein and that underphosphorylated pRb [Markiewicz et al., 2005] increases the transcriptional ability of MyoD family of muscle gene regulatory factors [Dick, 2007] . It has been proposed that a regulatory checkpoint in the terminal cell cycle arrest of myoblasts during differentiation involves the modulation of the cyclin D cdkdependent phosphorylation of pRb through the opposing effects of cyclin D1 and MyoD [Kitzmann and Fernandez, 2001 ].
Here, we have shown that during the first weeks of engraftment tumor cells express high levels of b1-integrin along with phosphorylated FAK. Thereafter, in time-when in the presence of matrigel tumor cells appear to be enriched with blood vessels and muscle fibers-stemness, proliferative potential, and pAKT levels potently decreased, while b1-integrin and pFAK still increased with pFAK accumulating in the nuclei. Concomitantly, nuclear b-catenin, c-Myc, and cyclin D2 markedly decreased and hyperphosphorylated pRb forms became unmeasurable, whereas total pRb levels did not change, thus suggesting a potent increase in underphosphorylated pRb form. Our findings suggest that matrigel, interacting with the subcutaneous microenvironment, might regulate 3AB-OS cell behavior providing the adequate cues for transducing either oncogenic or differentiation signals transmitted by pAKT, integrin, and pFAK and supported by pRb protein.
For several malignancies, tumor xenografts in mice have proven to be reliable tools to predict drug response in vivo and the drug industry has recognized the potential utility of tumorgrafts for screening drug candidates. Our results provide for the first time a model of subcutaneous tumor engraftment with human osteosarcoma CSCs. Our novel model seems to have the appropriate characteristics to serve as a promising tool to investigate osteosarcoma stem cell features and for appropriately targeting CSCs by identifying links between the engrafted cells and their microenvironment.
